- Home
- Latest
- By speciality
- Policy
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Education
- Most viewed
- View all
Latest
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Prof Alexander Eggermont - Erasmus University of Rotterdam, Netherlands
Advances in the treatment of melanoma
Prof Eggermont talks about the significance of ipilimumab. This monoclonal antibody, although developed to treat melanoma, could have important implications in the fight against many tumours. Ipilimumab affects tumours by modulates the immune system; activating a T-cell response that had been silenced. Considering this mechanism of action, ipilimumab could be effective in a much wider range of patients than personalised medicine and could be used against a number of different types of cancer. Prof Eggermont also discusses recent research into BRAF-inhibitors that has shown extremely high response rates among BRAF mutation-positive melanoma patients.
Speciality » Melanoma and skin
Other Specialities
- Policy (10)
- Biology (62)
- Bone (24)
- Brain and nervous system (14)
- Breast (190)
- Colorectal and gastrointestinal (43)
- Community (83)
- Diagnostics (37)
- Drug development (85)
- Epidemiology and prevention (53)
- Haematology oncology (60)
- Head and neck (17)
- Hepatobiliary pancreatic (17)
- Lung and pleura (47)
- Melanoma and skin (27)
- Ovary and gynaecology (33)
- Paediatric (17)
- Prostate and urology (42)
- Psycho social (19)
- Radiotherapy (27)
- Sarcomas (15)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment